Targeting role of glioma stem cells for glioblastoma multiforme

Current Medicinal Chemistry

Volumn 20, Issue 15, 2013, Pages 1974-1984

  Zhang, X ^a   Zhang, W ^a   Mao, X G ^a   Zhen, H N ^a   Cao, W D ^a   Hu, S J ^a  

^a FOURTH MILITARY MEDICAL UNIVERSITY   (China)

Author keywords

Antiangiogenisis; Cancer stem cell; CD133; Gene therapy; Glioblastoma multiforme; Glioma stem cells; Immunotherapy; MGMT; Temozolomide; Viral therapy

Indexed keywords

ALPHA6 INTEGRIN; BEVACIZUMAB; CARBOPLATIN; ETOPOSIDE; IRINOTECAN; PACLITAXEL; TEMOZOLOMIDE;

ANGIOGENESIS; ANTIANGIOGENIC THERAPY; ARTICLE; BLURRED VISION; BREAST METASTASIS; CANCER CHEMOTHERAPY; CANCER PROGNOSIS; CANCER RADIOTHERAPY; CANCER RECURRENCE; CANCER STEM CELL; CELL HETEROGENEITY; CLINICAL FEATURE; DENDRITIC CELL; DIZZINESS; GENE THERAPY; GENETIC SCREENING; GLIOBLASTOMA; GLIOMA STEM CELL; HEADACHE; HEMATOLOGIC DISEASE; HUMAN; IMMUNE RESPONSE; IMMUNOTHERAPY; KIDNEY CANCER; LUNG NON SMALL CELL CANCER; MENTAL DISEASE; METASTATIC COLORECTAL CANCER; NEURAL STEM CELL; NEUROLOGIC DISEASE; NONHUMAN; SEIZURE; T LYMPHOCYTE; TUMOR CELL; TUMOR GROWTH; TUMOR INVASION; VIROTHERAPY; VOMITING; WEAKNESS;

ANGIOGENESIS INHIBITORS; ANIMALS; BRAIN; BRAIN NEOPLASMS; GENETIC THERAPY; GLIOBLASTOMA; HUMANS; IMMUNOTHERAPY; NEOPLASTIC STEM CELLS; ONCOLYTIC VIROTHERAPY;

EID: 84877947874     PISSN: 09298673     EISSN: 1875533X     Source Type: Journal    
DOI: 10.2174/0929867311320150004     Document Type: Article

References (108)

1. Furnari, F.B.; Fenton, T.; Bachoo, R.M.; Mukasa, A.; Stommel, J.M.; Stegh, A.; Hahn, W.C.; Ligon, K.L.; Louis, D.N.; Brennan, C.; Chin, L.; DePinho, R.A.; Cavenee, W.K. Malignant astrocytic glioma: Genetics, biology, and paths to treatment. Genes. Dev., 2007, 21, 2683-2710. (Pubitemid 350070717)
2. Gurney, J.G.; Kadan-Lottick, N. Brain and other central nervous system tumors: Rates, trends, and epidemiology. Curr. Opin. Oncol., 2001, 13, 160-166. (Pubitemid 32433971)
3. Behin, A.; Hoang-Xuan, K.; Carpentier, A.F.; Delattre, J.Y. Primary brain tumours in adults. Lancet., 2003, 361, 323-331. (Pubitemid 36126198)
4. Watanabe, K.; Sato, K.; Biernat, W.; Tachibana, O.; von Ammon, K.; Ogata, N.; Yonekawa, Y.; Kleihues, P.; Ohgaki, H. Incidence and timing of p53 mutations during astrocytoma progression in patients with multiple biopsies. Clin. Cancer. Res., 1997, 3, 523-530. (Pubitemid 27211828)
5. Clarke, J.; Butowski, N.; Chang, S. Recent advances in therapy for glioblastoma. Arch. Neurol., 2010, 67, 279-283.
6. Ohgaki, H.; Dessen, P.; Jourde, B.; Horstmann, S.; Nishikawa, T.; Di Patre, P.L.; Burkhard, C.; Schuler, D.; Probst-Hensch, N.M.; Maiorka, P.C.; Baeza, N.; Pisani, P.; Yonekawa, Y.; Yasargil, M.G.; Lutolf, U.M.; Kleihues, P. Genetic pathways to glioblastoma: A population-based study. Cancer. Res., 2004, 64, 6892-6899. (Pubitemid 39330996)
7. Rekers, N.H.; Sminia, P.; Peters, G.J. Towards tailored therapy of glioblastoma multiforme. J. Chemother., 2011, 23, 187-199.
8. Wen, P.Y.; Kesari, S. Malignant gliomas in adults. N. Engl. J. Med., 2008, 359, 492-507.
9. Stupp, R.; Hegi, M.E.; Mason, W.P.; van den Bent, M.J.; Taphoorn, M.J.; Janzer, R.C.; Ludwin, S.K.; Allgeier, A.; Fisher, B.; Belanger, K.; Hau, P.; Brandes, A.A.; Gijtenbeek, J.; Marosi, C.; Vecht, C.J.; Mokhtari, K.; Wesseling, P.; Villa, S.; Eisenhauer, E.; Gorlia, T.; Weller, M.; Lacombe, D.; Cairncross, J.G.; Mirimanoff, R.O. Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial. Lancet. Oncol., 2009, 10, 459-466.
10. Cheng, L.; Wu, Q.; Guryanova, O.A.; Huang, Z.; Huang, Q.; Rich, J.N.; Bao, S. Elevated invasive potential of glioblastoma stem cells. Biochem. Biophys. Res. Commun., 2011, 406, 643-648.
11. Castro, M.G.; Candolfi, M.; Kroeger, K.; King, G.D.; Curtin, J.F.; Yagiz, K.; Mineharu, Y.; Assi, H.; Wibowo, M.; Ghulam Muhammad, A.K.; Foulad, D.; Puntel, M.; Lowenstein, P.R. Gene therapy and targeted toxins for glioma. Curr. Gene. Ther., 2011, 11, 155-180.
12. Singh, S.K.; Hawkins, C.; Clarke, I.D.; Squire, J.A.; Bayani, J.; Hide, T.; Henkelman, R.M.; Cusimano, M.D.; Dirks, P.B. Identification of human brain tumour initiating cells. Nature., 2004, 432, 396-401. (Pubitemid 39551674)
13. Hsieh, D. Collateral damage control in cancer therapy: Defining the stem identity in gliomas. Curr. Pharm. Des., 2011, 17, 2370-2385.
14. TCGA Comprehensive genomic characterization defines human glioblastoma genes and core pathways. Nature, 2008, 455, 1061-1068.
15. Piccirillo, S.G.; Binda, E.; Fiocco, R.; Vescovi, A.L.; Shah, K. Brain cancer stem cells. J. Mol. Med. (Berl.), 2009, 87, 1087-1095.
16. Lathia, J.D.; Gallagher, J.; Heddleston, J.M.; Wang, J.; Eyler, C.E.; Macswords, J.; Wu, Q.; Vasanji, A.; McLendon, R.E.; Hjelmeland, A.B.; Rich, J.N. Integrin alpha 6 regulates glioblastoma stem cells. Cell. Stem. Cell., 2010, 6, 421-432.
17. Grossman, S.A.; Batara, J.F. Current management of glioblastoma multiforme. Semin. Oncol., 2004, 31, 635-644. (Pubitemid 39389014)
18. Kanu, O.O.; Mehta, A.; Di, C.; Lin, N.; Bortoff, K.; Bigner, D.D.; Yan, H.; Adamson, D.C. Glioblastoma multiforme: A review of therapeutic targets. Expert. Opin. Ther. Targets., 2009, 13, 701-718.
19. Hanahan, D.; Weinberg, R.A. The hallmarks of cancer. Cell., 2000, 100, 57-70. (Pubitemid 30046295)
20. Nagarajan, R.P.; Costello, J.F. Epigenetic mechanisms in glioblastoma multiforme. Semin. Cancer. Biol., 2009, 19, 188-197.
21. Fulci, G.; Ishii, N.; Maurici, D.; Gernert, K.M.; Hainaut, P.; Kaur, B.; Van Meir, E.G. Initiation of human astrocytoma by clonal evolution of cells with progressive loss of p53 functions in a patient with a 283H TP53 germ-line mutation: Evidence for a precursor lesion. Cancer. Res., 2002, 62, 2897-2905. (Pubitemid 34525777)
22. Hill, C.; Hunter, S.B.; Brat, D.J. Genetic markers in glioblastoma: Prognostic significance and future therapeutic implications. Adv. Anat. Pathol., 2003, 10, 212-217.
23. Huang, Q.; Zhang, Q.B.; Dong, J.; Wu, Y.Y.; Shen, Y.T.; Zhao, Y.D.; Zhu, Y.D.; Diao, Y.; Wang, A.D.; Lan, Q. Glioma stem cells are more aggressive in recurrent tumors with malignant progression than in the primary tumor, and both can be maintained long-term in. vitro. BMC. Cancer., 2008, 8, 304.
24. Fujisawa, H.; Reis, R.M.; Nakamura, M.; Colella, S.; Yonekawa, Y.; Kleihues, P.; Ohgaki, H. Loss of heterozygosity on chromosome 10 is more extensive in primary (de novo) than in secondary glioblastomas. Lab. Invest., 2000, 80, 65-72. (Pubitemid 30067381)
25. Noushmehr, H.; Weisenberger, D.J.; Diefes, K.; Phillips, H.S.; Pujara, K.; Berman, B.P.; Pan, F.; Pelloski, C.E.; Sulman, E.P.; Bhat, K.P.; Verhaak, R.G.; Hoadley, K.A.; Hayes, D.N.; Perou, C.M.; Schmidt, H.K.; Ding, L.; Wilson, R.K.; Van Den Berg, D.; Shen, H.; Bengtsson, H.; Neuvial, P.; Cope, L.M.; Buckley, J.; Herman, J.G.; Baylin, S.B.; Laird, P.W.; Aldape, K. Identification of a CpG island methylator phenotype that defines a distinct subgroup of glioma. Cancer. Cell., 2010, 17, 510-522.
26. Schmidt, M.C.; Antweiler, S.; Urban, N.; Mueller, W.; Kuklik, A.; Meyer-Puttlitz, B.; Wiestler, O.D.; Louis, D.N.; Fimmers, R.; von Deimling, A. Impact of genotype and morphology on the prognosis of glioblastoma. J. Neuropathol. Exp. Neurol., 2002, 61, 321-328. (Pubitemid 34266783)
27. Albarosa, R.; Colombo, B.M.; Roz, L.; Magnani, I.; Pollo, B.; Cirenei, N.; Giani, C.; Conti, A.M.; DiDonato, S.; Finocchiaro, G. Deletion mapping of gliomas suggest the presence of two small regions for candidate tumor-suppressor genes in a 17-cM interval on chromosome 10q. Am. J. Hum. Genet., 1996, 58, 1260-1267. (Pubitemid 26153838)
28. von Deimling, A.; Louis, D.N.; von Ammon, K.; Petersen, I.; Hoell, T.; Chung, R.Y.; Martuza, R.L.; Schoenfeld, D.A.; Yasargil, M.G.; Wiestler, O.D.; et. al. Association of epidermal growth factor receptor gene amplification with loss of chromosome 10 in human glioblastoma multiforme. J. Neurosurg., 1992, 77, 295-301.
29. Parsons, D.W.; Jones, S.; Zhang, X.; Lin, J.C.; Leary, R.J.; Angenendt, P.; Mankoo, P.; Carter, H.; Siu, I.M.; Gallia, G.L.; Olivi, A.; McLendon, R.; Rasheed, B.A.; Keir, S.; Nikolskaya, T.; Nikolsky, Y.; Busam, D.A.; Tekleab, H.; Diaz, L.A., Jr.; Hartigan, J.; Smith, D.R.; Strausberg, R.L.; Marie, S.K.; Shinjo, S.M.; Yan, H.; Riggins, G.J.; Bigner, D.D.; Karchin, R.; Papadopoulos, N.; Parmigiani, G.; Vogelstein, B.; Velculescu, V.E.; Kinzler, K.W. An integrated genomic analysis of human glioblastoma multiforme. Science., 2008, 321, 1807-1812.
30. Zhao, S.; Lin, Y.; Xu, W.; Jiang, W.; Zha, Z.; Wang, P.; Yu, W.; Li, Z.; Gong, L.; Peng, Y.; Ding, J.; Lei, Q.; Guan, K.L.; Xiong, Y. Glioma-derived mutations in IDH1 dominantly inhibit IDH1 catalytic activity and induce HIF-1alpha. Science., 2009, 324, 261-265.
31. Lee, S.M.; Koh, H.J.; Park, D.C.; Song, B.J.; Huh, T.L.; Park, J.W. Cytosolic NADP(+)-dependent isocitrate dehydrogenase status modulates oxidative damage to cells. Free. Radic. Biol. Med., 2002, 32, 1185-1196. (Pubitemid 34603355)
32. Mao, X.G.; Yan, M.; Xue, X.Y.; Zhang, X.; Ren, H.G.; Guo, G.; Wang, P.; Zhang, W.; Huo, J.L. Overexpression of ZNF217 in glioblastoma contributes to the maintenance of glioma stem cells regulated by hypoxia-inducible factors. Lab. Invest., 2011, 91, 1068-1078.
33. Li, Z.; Bao, S.; Wu, Q.; Wang, H.; Eyler, C.; Sathornsumetee, S.; Shi, Q.; Cao, Y.; Lathia, J.; McLendon, R.E.; Hjelmeland, A.B.; Rich, J.N. Hypoxia-inducible factors regulate tumorigenic capacity of glioma stem cells. Cancer. Cell., 2009, 15, 501-513.
34. Bleeker, F.E.; Lamba, S.; Leenstra, S.; Troost, D.; Hulsebos, T.; Vandertop, W.P.; Frattini, M.; Molinari, F.; Knowles, M.; Cerrato, A.; Rodolfo, M.; Scarpa, A.; Felicioni, L.; Buttitta, F.; Malatesta, S.; Marchetti, A.; Bardelli, A. IDH1 mutations at residue p.R132 (IDH1(R132)) occur frequently in high-grade gliomas but not in other solid tumors. Hum. Mutat., 2009, 30, 7-11.
35. Kil, I.S.; Kim, S.Y.; Lee, S.J.; Park, J.W. Small interfering RNAmediated silencing of mitochondrial NADP+-dependent isocitrate dehydrogenase enhances the sensitivity of HeLa cells toward tumor necrosis factor-alpha and anticancer drugs. Free. Radic. Biol. Med., 2007, 43, 1197-1207. (Pubitemid 47374439)
36. Mao, X.G.; Zhang, X.; Zhen, H.N. Progress on potential strategies to target brain tumor stem cells. Cell. Mol. Neurobiol., 2009, 29, 141-155.
37. Vescovi, A.L.; Galli, R.; Reynolds, B.A. Brain tumour stem cells. Nat. Rev. Cancer., 2006, 6, 425-436.
38. Son, M.J.; Woolard, K.; Nam, D.H.; Lee, J.; Fine, H.A. SSEA-1 is an enrichment marker for tumor-initiating cells in human glioblastoma. Cell. Stem. Cell., 2009, 4, 440-452.
39. Mao, X.G.; Zhang, X.; Xue, X.Y.; Guo, G.; Wang, P.; Zhang, W.; Fei, Z.; Zhen, H.N.; You, S.W.; Yang, H. Brain Tumor Stem-Like Cells Identified by Neural Stem Cell Marker CD15. Transl. Oncol., 2009, 2, 247-257.
40. Bao, S.; Wu, Q.; Li, Z.; Sathornsumetee, S.; Wang, H.; McLendon, R.E.; Hjelmeland, A.B.; Rich, J.N. Targeting cancer stem cells through L1CAM suppresses glioma growth. Cancer. Res., 2008, 68, 6043-6048.
41. Binda, E.; Visioli, A.; Giani, F.; Lamorte, G.; Copetti, M.; Pitter, K.L.; Huse, J.T.; Cajola, L.; Zanetti, N.; DiMeco, F.; Filippis, L.D.; Mangiola, A.; Maira, G.; Anile, C.; De Bonis, P.; Reynolds, B.A.; Pasquale, E.B.; Vescovi, A.L. The EphA2 Receptor Drives Self-Renewal and Tumorigenicity in Stem-like Tumor-Propagating Cells from Human Glioblastomas. Cancer. Cell., 2012, 22, 765-780.
42. Zheng, H.; Ying, H.; Wiedemeyer, R.; Yan, H.; Quayle, S.N.; Ivanova, E.V.; Paik, J.H.; Zhang, H.; Xiao, Y.; Perry, S.R.; Hu, J.; Vinjamoori, A.; Gan, B.; Sahin, E.; Chheda, M.G.; Brennan, C.; Wang, Y.A.; Hahn, W.C.; Chin, L.; DePinho, R.A. PLAGL2 regulates Wnt signaling to impede differentiation in neural stem cells and gliomas. Cancer. Cell., 2010, 17, 497-509.
43. Hagerstrand, D.; He, X.; Bradic Lindh, M.; Hoefs, S.; Hesselager, G.; Ostman, A.; Nister, M. Identification of a SOX2-dependent subset of tumor-and sphere-forming glioblastoma cells with a distinct tyrosine kinase inhibitor sensitivity profile. Neuro. Oncol., 2011, 13, 1178-1191.
44. Natsume, A.; Kato, T.; Kinjo, S.; Enomoto, A.; Toda, H.; Shimato, S.; Ohka, F.; Motomura, K.; Kondo, Y.; Miyata, T.; Takahashi, M.; Wakabayashi, T. Girdin maintains the stemness of glioblastoma stem cells. Oncogene., 2012, 31, 2715-2724.
45. Bleau, A.M.; Hambardzumyan, D.; Ozawa, T.; Fomchenko, E.I.; Huse, J.T.; Brennan, C.W.; Holland, E.C. PTEN/PI3K/Akt pathway regulates the side population phenotype and ABCG2 activity in glioma tumor stem-like cells. Cell. Stem. Cell., 2009, 4, 226-235.
46. Hemmati, H.D.; Nakano, I.; Lazareff, J.A.; Masterman-Smith, M.; Geschwind, D.H.; Bronner-Fraser, M.; Kornblum, H.I. Cancerous stem cells can arise from pediatric brain tumors. Proc. Natl. Acad. Sci. U. S. A., 2003, 100, 15178-15183. (Pubitemid 37518036)
47. Klonisch, T.; Wiechec, E.; Hombach-Klonisch, S.; Ande, S.R.; Wesselborg, S.; Schulze-Osthoff, K.; Los, M. Cancer stem cell markers in common cancers -therapeutic implications. Trends. Mol. Med., 2008, 14, 450-460.
48. Eyler, C.E.; Foo, W.C.; LaFiura, K.M.; McLendon, R.E.; Hjelmeland, A.B.; Rich, J.N. Brain cancer stem cells display preferential sensitivity to Akt inhibition. Stem. Cells., 2008, 26, 3027-3036.
49. Liu, G.; Yuan, X.; Zeng, Z.; Tunici, P.; Ng, H.; Abdulkadir, I.R.; Lu, L.; Irvin, D.; Black, K.L.; Yu, J.S. Analysis of gene expression and chemoresistance of CD133+ cancer stem cells in glioblastoma. Mol. Cancer., 2006, 5, 67.
50. Gadji, M.; Crous, A.M.; Fortin, D.; Krcek, J.; Torchia, M.; Mai, S.; Drouin, R.; Klonisch, T. EGF receptor inhibitors in the treatment of glioblastoma multiform: Old clinical allies and newly emerging therapeutic concepts. Eur. J. Pharmacol., 2009, 625, 23-30.
51. Cheng, J.X.; Liu, B.L.; Zhang, X. How powerful is CD133 as a cancer stem cell marker in brain tumors? Cancer. Treat. Rev., 2009, 35, 403-408.
52. Chen, R.; Nishimura, M.C.; Bumbaca, S.M.; Kharbanda, S.; Forrest, W.F.; Kasman, I.M.; Greve, J.M.; Soriano, R.H.; Gilmour, L.L.; Rivers, C.S.; Modrusan, Z.; Nacu, S.; Guerrero, S.; Edgar, K.A.; Wallin, J.J.; Lamszus, K.; Westphal, M.; Heim, S.; James, C.D.; VandenBerg, S.R.; Costello, J.F.; Moorefield, S.; Cowdrey, C.J.; Prados, M.; Phillips, H.S. A hierarchy of self-renewing tumorinitiating cell types in glioblastoma. Cancer. Cell., 2010, 17, 362-375.
53. Read, T.A.; Fogarty, M.P.; Markant, S.L.; McLendon, R.E.; Wei, Z.; Ellison, D.W.; Febbo, P.G.; Wechsler-Reya, R.J. Identification of CD15 as a marker for tumor-propagating cells in a mouse model of medulloblastoma. Cancer. Cell., 2009, 15, 135-147.
54. Wu, Y.; Wu, P.Y. CD133 as a marker for cancer stem cells: Progresses and concerns. Stem. Cells. Dev., 2009, 18, 1127-1134.
55. Bidlingmaier, S.; Zhu, X.; Liu, B. The utility and limitations of glycosylated human CD133 epitopes in defining cancer stem cells. J. Mol. Med., 2008, 86, 1025-1032.
56. Ligon, K.L.; Huillard, E.; Mehta, S.; Kesari, S.; Liu, H.; Alberta, J.A.; Bachoo, R.M.; Kane, M.; Louis, D.N.; Depinho, R.A.; Anderson, D.J.; Stiles, C.D.; Rowitch, D.H. Olig2-regulated lineage-restricted pathway controls replication competence in neural stem cells and malignant glioma. Neuron., 2007, 53, 503-517. (Pubitemid 46216748)
57. Brescia, P.; Richichi, C.; Pelicci, G. Current strategies for identification of glioma stem cells: Adequate or unsatisfactory? J. Oncol., 2012, 2012, 376894.
58. Bao, S.; Wu, Q.; McLendon, R.E.; Hao, Y.; Shi, Q.; Hjelmeland, A.B.; Dewhirst, M.W.; Bigner, D.D.; Rich, J.N. Glioma stem cells promote radioresistance by preferential activation of the DNA damage response. Nature., 2006, 444, 756-760. (Pubitemid 44949604)
59. Dean, M.; Fojo, T.; Bates, S. Tumour stem cells and drug resistance. Nat. Rev. Cancer., 2005, 5, 275-284. (Pubitemid 40488633)
60. Eyler, C.E.; Rich, J.N. Survival of the fittest: Cancer stem cells in therapeutic resistance and angiogenesis. J. Clin. Oncol., 2008, 26, 2839-2845.
61. Darnell, J.E., Jr. Transcription factors as targets for cancer therapy. Nat. Rev. Cancer., 2002, 2, 740-749.
62. Zhang, Z.; Li, M.; Rayburn, E.R.; Hill, D.L.; Zhang, R.; Wang, H. Oncogenes as novel targets for cancer therapy (part III): Transcription factors. Am. J. Pharmacogenomics., 2005, 5, 327-338. (Pubitemid 41430311)
63. Reardon, D.A.; Wen, P.Y.; Desjardins, A.; Batchelor, T.T.; Vredenburgh, J.J. Glioblastoma multiforme: An emerging paradigm of anti-VEGF therapy. Expert. Opin. Biol. Ther., 2008, 8, 541-553. (Pubitemid 351570416)
64. Bao, S.; Wu, Q.; Sathornsumetee, S.; Hao, Y.; Li, Z.; Hjelmeland, A.B.; Shi, Q.; McLendon, R.E.; Bigner, D.D.; Rich, J.N. Stem celllike glioma cells promote tumor angiogenesis through vascular endothelial growth factor. Cancer. Res., 2006, 66, 7843-7848. (Pubitemid 44299144)
65. Soda, Y.; Marumoto, T.; Friedmann-Morvinski, D.; Soda, M.; Liu, F.; Michiue, H.; Pastorino, S.; Yang, M.; Hoffman, R.M.; Kesari, S.; Verma, I.M. Transdifferentiation of glioblastoma cells into vascular endothelial cells. Proc. Natl. Acad. Sci. U. S. A., 2011, 108, 4274-4280.
66. Wang, R.; Chadalavada, K.; Wilshire, J.; Kowalik, U.; Hovinga, K.E.; Geber, A.; Fligelman, B.; Leversha, M.; Brennan, C.; Tabar, V. Glioblastoma stem-like cells give rise to tumour endothelium. Nature., 2010, 468, 829-833.
67. Ricci-Vitiani, L.; Pallini, R.; Biffoni, M.; Todaro, M.; Invernici, G.; Cenci, T.; Maira, G.; Parati, E.A.; Stassi, G.; Larocca, L.M.; De Maria, R. Tumour vascularization via endothelial differentiation of glioblastoma stem-like cells. Nature., 2010, 468, 824-828.
68. Seidel, S.; Garvalov, B.K.; Wirta, V.; von Stechow, L.; Schanzer, A.; Meletis, K.; Wolter, M.; Sommerlad, D.; Henze, A.T.; Nister, M.; Reifenberger, G.; Lundeberg, J.; Frisen, J.; Acker, T. A hypoxic niche regulates glioblastoma stem cells through hypoxia inducible factor 2 alpha. Brain., 2010, 133, 983-995.
69. Folkins, C.; Shaked, Y.; Man, S.; Tang, T.; Lee, C.R.; Zhu, Z.; Hoffman, R.M.; Kerbel, R.S. Glioma tumor stem-like cells promote tumor angiogenesis and vasculogenesis via vascular endothelial growth factor and stromal-derived factor 1. Cancer. Res., 2009, 69, 7243-7251.
70. Jain, R.K.; di Tomaso, E.; Duda, D.G.; Loeffler, J.S.; Sorensen, A.G.; Batchelor, T.T. Angiogenesis in brain tumours. Nat. Rev. Neurosci., 2007, 8, 610-622. (Pubitemid 47093931)
71. De Fazio, S.; Russo, E.; Ammendola, M.; Donato Di Paola, E.; De Sarro, G. Efficacy and safety of bevacizumab in glioblastomas. Curr. Med. Chem., 2012, 19, 972-981.
72. Spinelli, G.P.; Miele, E.; Russo, G.L.; Miscusi, M.; Codacci-Pisanelli, G.; Petrozza, V.; Papa, A.; Frati, L.; Della Rocca, C.; Gulino, A.; Tomao, S. Chemotherapy and target therapy in the management of adult high-grade gliomas. Curr. Cancer. Drug. Targets., 2012, 12, 1016-1031.
73. Huang, Z.; Cheng, L.; Guryanova, O.A.; Wu, Q.; Bao, S. Cancer stem cells in glioblastoma-molecular signaling and therapeutic targeting. Protein. Cell., 2010, 1, 638-655.
74. Friedman, H.S.; Prados, M.D.; Wen, P.Y.; Mikkelsen, T.; Schiff, D.; Abrey, L.E.; Yung, W.K.; Paleologos, N.; Nicholas, M.K.; Jensen, R.; Vredenburgh, J.; Huang, J.; Zheng, M.; Cloughesy, T. Bevacizumab alone and in combination with irinotecan in recurrent glioblastoma. J. Clin. Oncol., 2009, 27, 4733-4740.
75. Batchelor, T.T.; Sorensen, A.G.; di Tomaso, E.; Zhang, W.T.; Duda, D.G.; Cohen, K.S.; Kozak, K.R.; Cahill, D.P.; Chen, P.J.; Zhu, M.; Ancukiewicz, M.; Mrugala, M.M.; Plotkin, S.; Drappatz, J.; Louis, D.N.; Ivy, P.; Scadden, D.T.; Benner, T.; Loeffler, J.S.; Wen, P.Y.; Jain, R.K. AZD2171, a pan-VEGF receptor tyrosine kinase inhibitor, normalizes tumor vasculature and alleviates edema in glioblastoma patients. Cancer. Cell., 2007, 11, 83-95. (Pubitemid 46075199)
76. Vredenburgh, J.J.; Desjardins, A.; Herndon, J.E., 2nd; Dowell, J.M.; Reardon, D.A.; Quinn, J.A.; Rich, J.N.; Sathornsumetee, S.; Gururangan, S.; Wagner, M.; Bigner, D.D.; Friedman, A.H.; Friedman, H.S. Phase II trial of bevacizumab and irinotecan in recurrent malignant glioma. Clin. Cancer. Res., 2007, 13, 1253-1259. (Pubitemid 46424067)
77. Keunen, O.; Johansson, M.; Oudin, A.; Sanzey, M.; Rahim, S.A.; Fack, F.; Thorsen, F.; Taxt, T.; Bartos, M.; Jirik, R.; Miletic, H.; Wang, J.; Stieber, D.; Stuhr, L.; Moen, I.; Rygh, C.B.; Bjerkvig, R.; Niclou, S.P. Anti-VEGF treatment reduces blood supply and increases tumor cell invasion in glioblastoma. Proc. Natl. Acad. Sci. U. S. A., 2011, 108, 3749-3754.
78. Vredenburgh, J.J.; Desjardins, A.; Herndon, J.E., 2nd; Marcello, J.; Reardon, D.A.; Quinn, J.A.; Rich, J.N.; Sathornsumetee, S.; Gururangan, S.; Sampson, J.; Wagner, M.; Bailey, L.; Bigner, D.D.; Friedman, A.H.; Friedman, H.S. Bevacizumab plus irinotecan in recurrent glioblastoma multiforme. J. Clin. Oncol., 2007, 25, 4722-4729. (Pubitemid 350086473)
79. Fruehauf, J.P.; Brem, H.; Brem, S.; Sloan, A.; Barger, G.; Huang, W.; Parker, R. In. vitro drug response and molecular markers associated with drug resistance in malignant gliomas. Clin. Cancer. Res., 2006, 12, 4523-4532. (Pubitemid 44297801)
80. Quinn, J.A.; Jiang, S.X.; Reardon, D.A.; Desjardins, A.; Vredenburgh, J.J.; Gururangan, S.; Sampson, J.H.; McLendon, R.E.; Herndon, J.E., 2nd; Friedman, H.S. Phase 1 trial of temozolomide plus irinotecan plus O6-benzylguanine in adults with recurrent malignant glioma. Cancer., 2009, 115, 2964-2970.
81. Amundson, S.A.; Patterson, A.; Do, K.T.; Fornace, A.J., Jr. A nucleotide excision repair master-switch: P53 regulated coordinate induction of global genomic repair genes. Cancer. Biol. Ther., 2002, 1, 145-149.
82. Bocangel, D.B.; Finkelstein, S.; Schold, S.C.; Bhakat, K.K.; Mitra, S.; Kokkinakis, D.M. Multifaceted resistance of gliomas to temozolomide. Clin. Cancer. Res., 2002, 8, 2725-2734. (Pubitemid 34856362)
83. Hegi, M.E.; Diserens, A.C.; Gorlia, T.; Hamou, M.F.; de Tribolet, N.; Weller, M.; Kros, J.M.; Hainfellner, J.A.; Mason, W.; Mariani, L.; Bromberg, J.E.; Hau, P.; Mirimanoff, R.O.; Cairncross, J.G.; Janzer, R.C.; Stupp, R. MGMT gene silencing and benefit from temozolomide in glioblastoma. N. Engl. J. Med., 2005, 352, 997-1003. (Pubitemid 40349502)
84. Ohka, F.; Natsume, A.; Wakabayashi, T. Current trends in targeted therapies for glioblastoma multiforme. Neurol. Res. Int., 2012, 2012, 878425.
85. Sato, A.; Sunayama, J.; Matsuda, K.; Seino, S.; Suzuki, K.; Watanabe, E.; Tachibana, K.; Tomiyama, A.; Kayama, T.; Kitanaka, C. MEK-ERK signaling dictates DNA-repair gene MGMT expression and temozolomide resistance of stem-like glioblastoma cells via the MDM2-p53 axis. Stem. Cells., 2011, 29, 1942-1951.
86. Blough, M.D.; Beauchamp, D.C.; Westgate, M.R.; Kelly, J.J.; Cairncross, J.G. Effect of aberrant p53 function on temozolomide sensitivity of glioma cell lines and brain tumor initiating cells from glioblastoma. J. Neurooncol., 2011, 102, 1-7.
87. Natsume, A.; Ishii, D.; Wakabayashi, T.; Tsuno, T.; Hatano, H.; Mizuno, M.; Yoshida, J. IFN-beta down-regulates the expression of DNA repair gene MGMT and sensitizes resistant glioma cells to temozolomide. Cancer. Res., 2005, 65, 7573-7579. (Pubitemid 41297227)
88. Chen, J.; Li, Y.; Yu, T.S.; McKay, R.M.; Burns, D.K.; Kernie, S.G.; Parada, L.F. A restricted cell population propagates glioblastoma growth after chemotherapy. Nature., 2012, 488, 522-526.
89. Natsume, A.; Kinjo, S.; Yuki, K.; Kato, T.; Ohno, M.; Motomura, K.; Iwami, K.; Wakabayashi, T. Glioma-initiating cells and molecular pathology: Implications for therapy. Brain. Tumor. Pathol., 2011, 28, 1-12.
90. Ginestier, C.; Hur, M.H.; Charafe-Jauffret, E.; Monville, F.; Dutcher, J.; Brown, M.; Jacquemier, J.; Viens, P.; Kleer, C.G.; Liu, S.; Schott, A.; Hayes, D.; Birnbaum, D.; Wicha, M.S.; Dontu, G. ALDH1 is a marker of normal and malignant human mammary stem cells and a predictor of poor clinical outcome. Cell. Stem. Cell., 2007, 1, 555-567. (Pubitemid 350056407)
91. Gilbertson, R.J.; Rich, J.N. Making a tumour's bed: Glioblastoma stem cells and the vascular niche. Nat. Rev. Cancer., 2007, 7, 733-736. (Pubitemid 47463683)
92. Hoey, T.; Yen, W.C.; Axelrod, F.; Basi, J.; Donigian, L.; Dylla, S.; Fitch-Bruhns, M.; Lazetic, S.; Park, I.K.; Sato, A.; Satyal, S.; Wang, X.; Clarke, M.F.; Lewicki, J.; Gurney, A. DLL4 blockade inhibits tumor growth and reduces tumor-initiating cell frequency. Cell. Stem. Cell., 2009, 5, 168-177.
93. Palucka, K.; Banchereau, J. Cancer immunotherapy via dendritic cells. Nat. Rev. Cancer., 2012, 12, 265-277.
94. Boon, T.; Coulie, P.G.; Van den Eynde, B. Tumor antigens recognized by T cells. Immunol. Today., 1997, 18, 267-268. (Pubitemid 27261443)
95. Daga, A.; Bottino, C.; Castriconi, R.; Gangemi, R.; Ferrini, S. New perspectives in glioma immunotherapy. Curr. Pharm. Des., 2011, 17, 2439-2467.
96. Dunning, N.L.; Laversin, S.A.; Miles, A.K.; Rees, R.C. Immunotherapy of prostate cancer: Should we be targeting stem cells and EMT? Cancer. Immunol. Immunother., 2011, 60, 1181-1193.
97. Frosina, G. Frontiers in targeting glioma stem cells. Eur. J. Cancer., 2011, 47, 496-507.
98. Gilboa, E. DC-based cancer vaccines. J. Clin. Invest., 2007, 117, 1195-1203. (Pubitemid 46718404)
99. Avril, T.; Vauleon, E.; Hamlat, A.; Saikali, S.; Etcheverry, A.; Delmas, C.; Diabira, S.; Mosser, J.; Quillien, V. Human glioblastoma stem-like cells are more sensitive to allogeneic NK and T cell-mediated killing compared with serum-cultured glioblastoma cells. Brain. Pathol., 2012, 22, 159-174.
100. Dey, M.; Ulasov, I.V.; Lesniak, M.S. Virotherapy against malignant glioma stem cells. Cancer. Lett., 2010, 289, 1-10.
101. Rainov, N.G.; Heidecke, V. Clinical development of experimental virus-mediated gene therapy for malignant glioma. Anticancer. Agents. Med. Chem., 2011, 11, 739-747.
102. Aghi, M.; Martuza, R.L. Oncolytic viral therapies -the clinical experience. Oncogene., 2005, 24, 7802-7816. (Pubitemid 41670681)
103. Wakimoto, H.; Kesari, S.; Farrell, C.J.; Curry, W.T., Jr.; Zaupa, C.; Aghi, M.; Kuroda, T.; Stemmer-Rachamimov, A.; Shah, K.; Liu, T.C.; Jeyaretna, D.S.; Debasitis, J.; Pruszak, J.; Martuza, R.L.; Rabkin, S.D. Human glioblastoma-derived cancer stem cells: Establishment of invasive glioma models and treatment with oncolytic herpes simplex virus vectors. Cancer. Res., 2009, 69, 3472-3481.
104. Santra, M.; Zheng, X.; Roberts, C.; Santra, S.; Lu, M.; Panda, S.; Jiang, F.; Chopp, M. Single doublecortin gene therapy significantly reduces glioma tumor volume. J. Neurosci. Res., 2010, 88, 304-314.
105. Zhang, W.; Fulci, G.; Buhrman, J.S.; Stemmer-Rachamimov, A.O.; Chen, J.W.; Wojtkiewicz, G.R.; Weissleder, R.; Rabkin, S.D.; Martuza, R.L. Bevacizumab with angiostatin-armed oHSV increases antiangiogenesis and decreases bevacizumab-induced invasion in U87 glioma. Mol. Ther., 2012, 20, 37-45.
106. Wang, Z.Y.; Chen, Z. Acute promyelocytic leukemia: From highly fatal to highly curable. Blood., 2008, 111, 2505-2515.
107. Sachlos, E.; Risueno, R.M.; Laronde, S.; Shapovalova, Z.; Lee, J.H.; Russell, J.; Malig, M.; McNicol, J.D.; Fiebig-Comyn, A.; Graham, M.; Levadoux-Martin, M.; Lee, J.B.; Giacomelli, A.O.; Hassell, J.A.; Fischer-Russell, D.; Trus, M.R.; Foley, R.; Leber, B.; Xenocostas, A.; Brown, E.D.; Collins, T.J.; Bhatia, M. Identification of drugs including a dopamine receptor antagonist that selectively target cancer stem cells. Cell., 2012, 149, 1284-1297.
108. Carro, M.S.; Lim, W.K.; Alvarez, M.J.; Bollo, R.J.; Zhao, X.; Snyder, E.Y.; Sulman, E.P.; Anne, S.L.; Doetsch, F.; Colman, H.; Lasorella, A.; Aldape, K.; Califano, A.; Iavarone, A. The transcriptional network for mesenchymal transformation of brain tumours. Nature., 2010, 463, 318-325.